Acquired Bleeding Disorder Completed Phase 2 Trials for Coagulation factor VII human (DB13150)

IndicationStatusPhase
DBCOND0030736 (Acquired Bleeding Disorder)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00102037Use of Activated Recombinant FVII in Spinal SurgeryTreatment
NCT00123591Safety and Preliminary Efficacy of Recombinant Activated Factor VII in Subjects With Traumatic Brain InjuryTreatment
NCT00154492Use of NovoSeven® in Active Variceal BleedingTreatment
NCT00266006Factor VIIa in Acute Intracerebral HaemorrhageTreatment
NCT00426803Recombinant Factor VIIa in Acute Intracerebral HaemorrhageTreatment
NCT01562821Safety and Efficacy of Activated Recombinant Human Factor VII in Cirrhotic Patients Undergoing Partial HepatectomyTreatment
NCT01562158Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Allogeneic Stem Cell TransplantationTreatment
NCT01563445Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII for Preventing Early Hematoma Growth in Acute Intracerebral HaemorrhageTreatment
NCT01563458Safety and Efficacy of Activated Recombinant Human Factor VII in Patients Undergoing Orthotopic Liver TransplantationTreatment
NCT01563523Efficacy and Safety of Activated Recombinant Human Factor VII in Severely Injured Trauma PatientsTreatment
NCT01566786Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII in Acute Intracerebral HaemorrhageTreatment
NCT01601457Activated Recombinant Human Factor VII in Pelvic-acetabular Fracture ReconstructionTreatment
NCT01601613Activated Recombinant Human Factor VII in Patients With Dengue Haemorrhagic FeverTreatment